NC-BIO-GENE
Bio-Gene Technology Limited (ASX:BGT or ‘Bio-Gene’), an Australian company developing the next generation of novel bio-insecticides, and Envu are evaluating Flavocide™ for use in professional pest management and public health products to control mosquitoes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240813495113/en/
Vector-borne diseases account for more than 17% of all infectious diseases, causing more than 700 000 deaths annually. They can be caused by either parasites, bacteria or viruses. Malaria is a parasitic infection transmitted by Anopheline mosquitoes. It causes an estimated 219 million cases globally, and results in more than 400,000 deaths every year. Most of the deaths occur in children under the age of 5 years. (Photo: Business Wire)
Envu, a global company dedicated to environmental science, develops innovative solutions to manage insects, weeds and turf diseases that threaten public health and environments. Through its ESG pillars, Envu is committed to nature-positive innovation. As a nature-identical compound, Flavocide complements the company’s professional pest and mosquito management product portfolios.
This collaboration combines Bio-Gene’s discovery and development pipeline with the formulation expertise of Envu to maximize efficacy and application efficiency. Bio-Gene and Envu have successfully evaluated several formulations of Flavocide to target mosquitoes and will continue to evaluate Flavocide for a range of professional use products to control these public health pests.
Tim Grogan, Managing Director & Chief Executive Officer for Bio-Gene said: “Our work with Envu extends the potential for Flavocide to be used in major professional pest management and public health target markets worldwide for the control of mosquitoes. Envu is a world leader in the commercial development and marketing of new and sustainable products to combat mosquitoes. This important program supports our strategy of engaging with a range of strong partners to fully exploit the opportunities available for our technologies.”
Bernard Jacqmin, Senior Vice President - Head of Global Innovation for Envu said: “We are pleased to be working with Bio-Gene and to formulate and evaluate Flavocide for use in mosquito management applications. Flavocide is derived from nature and, based on our testing completed to date, has demonstrated a favorable profile to combat mosquitoes. Our combined efforts are already showing promising results in the testing phase, and we are excited about the potential benefits for consumers and professionals in the field."
Flavocide is a nature-identical product based on Flavesone, a naturally occurring plant compound present in some eucalypts. Bio-Gene has developed a proprietary process to synthesize the molecule and produce it in commercial quantities.
Flavocide exhibits a new mode of action – that is, the way an insecticide controls or knocks down an insect - and is able to overcome insect resistance to current insecticidal products. Mosquito strains can become particularly resistant to existing products, making it challenging to manage the spread of serious diseases such as Malaria, Dengue fever and Zika virus. Insecticides with new modes of action are rare and are essential to ensure future global food security and public health.
Bio-Gene is developing Flavocide to address the major worldwide problem of insecticide resistance in the areas of public health, crop protection, grain storage and consumer applications.
At this time, Bio-Gene and Envu are exploring opportunities for Envu to use Flavocide in commercial product(s). Any future development or licensing agreements will be jointly announced by Bio-Gene and Envu.
Approved for release by Bio-Gene and by Envu.
About Bio-Gene Technology Limited
Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.
Bio-Gene’s products have multiple applications across crop protection, grain storage, public health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.
Flavocide™ is a trademark of Bio-Gene Technology Limited.
About Envu
Envu was founded in 2022, a company built on years of environmental science experience, for the sole purpose of advancing healthy environments for everyone, everywhere. Envu offers dedicated services in: Professional Pest Management, Forestry, Ornamentals, Golf, Industrial Vegetation Management, Lawn & Landscape, Mosquito Management, and Range & Pasture. Envu collaborates with customers to design innovative solutions that meet their requirements today and well into the future. The Envu portfolio consists of over 180 trusted and well-known brands. The company employs 900 people, operates in 100 countries and has four global innovation hubs. For additional information, visit www.envu.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813495113/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mastering Complexity & Increasing Efficiency: CES 2026: dSPACE Demonstrates Test and AI Solutions for SDV Development16.12.2025 14:02:00 CET | Press release
At CES 2026, dSPACE will showcase end-to-end test solutions that enable vehicle manufacturers to efficiently master the increasing complexity in the development of software-defined vehicles. At booth 4500 in West Hall, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated vehicle development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216117958/en/ At CES 2026, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated SDV development. AI is a strategic enabler throughout the entire development and test process. dSPACE has been exploring how the latest developments in generative and agentic AI technologies can support software-in-the-loop (SIL) testing and enable CI/CD pipelines for automated validation. In an exhibit, dSPACE will demonstra
PPG achieves REDCert² sustainable raw material certification at two key European sites16.12.2025 14:01:00 CET | Press release
PPG (NYSE: PPG) today announced that its Architectural Coatings manufacturing sites in Amsterdam, the Netherlands and Søborg, Denmark have received REDCert² certification, which verifies the use of sustainable raw materials through a certified chain of custody. REDCert² uses the mass balance approach, a recognized method for attributing the sustainability value of certified inputs. This ensures that PPG’s products reflect responsible sourcing throughout the manufacturing process and reinforces the company’s commitment to delivering high-performing, sustainably advantaged solutions to customers across Europe. “This certification supports our broader goal of integrating sustainability and productivity into our operations and our commitment to transparent manufacturing,” said Mats Hagerstrom, PPG head of sustainability, EMEA, Architectural Coatings. “It helps us deliver products that meet high performance standards while supporting our customers’ environmental objectives.” The certified s
FIFA World Cup™ Trophy Tour by Coca-Cola to Begin Global Journey Ahead of FIFA World Cup 2026™16.12.2025 14:00:00 CET | Press release
Coca-Cola and FIFA celebrate 20 years of FIFA World Cup™ Trophy Tour by Coca-Cola The Coca-Cola Company and FIFA are kicking off the sixth FIFA World Cup™ Trophy Tour by Coca-Cola, giving thousands of fans across the globe the opportunity to see the original FIFA World Cup™ Trophy ahead of FIFA World Cup 2026™. FIFA World Cup 2026 is set to be the biggest yet—spanning three host nations, Canada, Mexico and the United States, with more teams, more matches and more celebrations than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216393608/en/ FIFA World Cup™ Trophy Tour by Coca-Cola As a long-standing partner of FIFA, Coca-Cola has the exclusive rights to the FIFA World Cup Trophy Tour by Coca-Cola. Beginning Jan. 3, 2026, in Riyadh, Saudi Arabia, the original FIFA World Cup Trophy will visit 30 FIFA Member Associations across 75 stops and more than 150 tour days, giving fans around the world a once-in-a-lifeti
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom